Detail Information of Transcriptional Regulations

General Information of Drug Transporter (DT)
DT ID DTD0521 Transporter Info
Gene Name CACNA2D3
Transporter Name Voltage-dependent calcium channel alpha-2/delta-3
Gene ID
55799
UniProt ID
Q9NY16

Transcriptional Regulation of This DT (TSR)

TF Superclass1: Basic domains

      Class1.1: Basic leucine zipper factors

Click to Show/Hide the Full List of 2 TF(s) Regulating This DT

        BACH1 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Activation of CACNA2D3 gene in breast cancer bone metastasis condition [1]

TF Protein Name

 Transcription regulator protein BACH1 Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Up regulating

Detailed Description

 Transcription regulator protein BACH1 (BACH1) has been reported to activate the transcription of CACNA2D3 gene in breast cancer bone metastasis condition, which leads to an increased expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

        CEBPB 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Direct binding to CACNA2D3 gene [2]

TF Protein Name

 CCAAT/enhancer-binding protein beta Transcription Factor Info

Tissue

 Bone

Related DT Changes

 Direct regulating

Experiment method

 TF-transporter regulations were collected from ChIP-Seq datasets.

Detailed Description

 CCAAT/enhancer-binding protein beta (CEBPB) can directly bind to the CACNA2D3 gene, which in turn affects the expression or function of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

      Class1.2: Basic helix-loop-helix factors

Click to Show/Hide the Full List of 1 TF(s) Regulating This DT

        TCF4 

Click to Show/Hide to Show 2 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Activation of CACNA2D3 gene in colorectal cancer condition [3]

TF Protein Name

 Transcription factor 4 Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Up regulating

Detailed Description

 Transcription factor 4 (TCF4) has been reported to activate the transcription of CACNA2D3 gene in colorectal cancer condition, which leads to an increased expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

       Transcriptional Phenomenon2

 Activation of CACNA2D3 gene in glioblastoma multiforme condition [4]

TF Protein Name

 Transcription factor 4 Transcription Factor Info

Affected Drug/Substrate

 Temozolomide

Studied Phenotype

 .

Related DT Changes

 Up regulating

Detailed Description

 Transcription factor 4 (TCF4) has been reported to activate the transcription of CACNA2D3 gene in glioblastoma multiforme condition, which leads to an increased expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

TF Superclass2: Zinc-coordinating DNA-binding domains

      Class2.1: Nuclear receptors with C4 zinc fingers

Click to Show/Hide the Full List of 1 TF(s) Regulating This DT

        AR 

Click to Show/Hide to Show 3 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Activation of CACNA2D3 gene in prostate cancer condition [5]

TF Protein Name

 Androgen receptor Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Up regulating

Detailed Description

 Androgen receptor (AR) has been reported to activate the transcription of CACNA2D3 gene in prostate cancer condition, which leads to an increased expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

       Transcriptional Phenomenon2

 Binding to CACNA2D3 gene in prostate cancer condition [6]

TF Protein Name

 Androgen receptor Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Direct regulating

Detailed Description

 Androgen receptor (AR) has been reported to bind to the transcription of CACNA2D3 gene in prostate cancer condition, which leads to an affected expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

       Transcriptional Phenomenon3

 Binding to CACNA2D3 gene in prostate cancer condition [7]

TF Protein Name

 Androgen receptor Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Direct regulating

Detailed Description

 Androgen receptor (AR) has been reported to bind to the transcription of CACNA2D3 gene in prostate cancer condition, which leads to an affected expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

      Class2.2: Other C4 zinc finger-type factors

Click to Show/Hide the Full List of 2 TF(s) Regulating This DT

        GATA1 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Binding to CACNA2D3 gene in megakaryocytes condition [8]

TF Protein Name

 Erythroid transcription factor Transcription Factor Info

Related DT Changes

 Direct regulating

Detailed Description

 Erythroid transcription factor (GATA1) has been reported to bind to the transcription of CACNA2D3 gene in megakaryocytes condition, which leads to an affected expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

        GATA6 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Activation of CACNA2D3 gene in gastric cancer condition [9]

TF Protein Name

 Transcription factor GATA-6 Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Up regulating

Detailed Description

 Transcription factor GATA-6 (GATA6) has been reported to activate the transcription of CACNA2D3 gene in gastric cancer condition, which leads to an increased expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

      Class2.3: C2H2 zinc finger factors

Click to Show/Hide the Full List of 4 TF(s) Regulating This DT

        BCL6 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Activation of CACNA2D3 gene in health condition [10]

TF Protein Name

 B-cell lymphoma 6 protein Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Up regulating

Detailed Description

 B-cell lymphoma 6 protein (BCL6) has been reported to activate the transcription of CACNA2D3 gene in health condition, which leads to an increased expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

        EGR1 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Binding to CACNA2D3 gene in erythroleukemia condition [11]

TF Protein Name

 Early growth response protein 1 Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Direct regulating

Detailed Description

 Early growth response protein 1 (EGR1) has been reported to bind to the transcription of CACNA2D3 gene in erythroleukemia condition, which leads to an affected expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

        WT1 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Activation of CACNA2D3 gene in podocyte condition [12]

TF Protein Name

 Wilms tumor protein Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Up regulating

Detailed Description

 Wilms tumor protein (WT1) has been reported to activate the transcription of CACNA2D3 gene in podocyte condition, which leads to an increased expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

        ZNF217 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Binding to CACNA2D3 gene in breast cancer condition [13]

TF Protein Name

 Zinc finger protein 217 Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Direct regulating

Detailed Description

 Zinc finger protein 217 (ZNF217) has been reported to bind to the transcription of CACNA2D3 gene in breast cancer condition, which leads to an affected expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

TF Superclass3: Helix-turn-helix domains

      Class3.3: Fork head / winged helix factors

Click to Show/Hide the Full List of 3 TF(s) Regulating This DT

        FOXA1 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Binding to CACNA2D3 gene in prostate cancer condition [14]

TF Protein Name

 Hepatocyte nuclear factor 3-alpha Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Direct regulating

Detailed Description

 Hepatocyte nuclear factor 3-alpha (FOXA1) has been reported to bind to the transcription of CACNA2D3 gene in prostate cancer condition, which leads to an affected expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

        FOXA2 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Binding to CACNA2D3 gene in health condition [15]

TF Protein Name

 Hepatocyte nuclear factor 3-beta Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Direct regulating

Detailed Description

 Hepatocyte nuclear factor 3-beta (FOXA2) has been reported to bind to the transcription of CACNA2D3 gene in health condition, which leads to an affected expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

        FOXM1 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Activation of CACNA2D3 gene in breast cancer condition [16]

TF Protein Name

 Forkhead box protein M1 Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Up regulating

Detailed Description

 Forkhead box protein M1 (FOXM1) has been reported to activate the transcription of CACNA2D3 gene in breast cancer condition, which leads to an increased expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

TF Superclass6: Immunoglobulin fold

      Class6.2: STAT domain factors

Click to Show/Hide the Full List of 1 TF(s) Regulating This DT

        STAT3 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Binding to CACNA2D3 gene in glioblastoma multiforme condition [4]

TF Protein Name

 Signal transducer and activator of transcription 3 Transcription Factor Info

Affected Drug/Substrate

 Temozolomide

Studied Phenotype

 .

Related DT Changes

 Direct regulating

Detailed Description

 Signal transducer and activator of transcription 3 (STAT3) has been reported to bind to the transcription of CACNA2D3 gene in glioblastoma multiforme condition, which leads to an affected expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

      Class6.3: p53 domain factors

Click to Show/Hide the Full List of 1 TF(s) Regulating This DT

        TP63 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Binding to CACNA2D3 gene in health condition [17]

TF Protein Name

 Tumor protein 63 Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Direct regulating

Detailed Description

 Tumor protein 63 (TP63) has been reported to bind to the transcription of CACNA2D3 gene in health condition, which leads to an affected expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

      Class6.4: Runt domain factors

Click to Show/Hide the Full List of 2 TF(s) Regulating This DT

        RUNX1 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Binding to CACNA2D3 gene in megakaryocytes condition [8]

TF Protein Name

 Runt-related transcription factor 1 Transcription Factor Info

Related DT Changes

 Direct regulating

Detailed Description

 Runt-related transcription factor 1 (RUNX1) has been reported to bind to the transcription of CACNA2D3 gene in megakaryocytes condition, which leads to an affected expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

        RUNX2 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Activation of CACNA2D3 gene in prostate cancer condition [18]

TF Protein Name

 Runt-related transcription factor 2 Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Up regulating

Detailed Description

 Runt-related transcription factor 2 (RUNX2) has been reported to activate the transcription of CACNA2D3 gene in prostate cancer condition, which leads to an increased expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.

TF Superclass7: beta-Hairpin exposed by an alpha/beta-scaffold

      Class7.1: SMAD/NF-1 DNA-binding domain factors

Click to Show/Hide the Full List of 1 TF(s) Regulating This DT

        SMAD4 

Click to Show/Hide to Show 1 Transcriptional Phenomena      

       Transcriptional Phenomenon1

 Activation of CACNA2D3 gene in epithelial ovarian cancer condition [19]

TF Protein Name

 Mothers against decapentaplegic homolog 4 Transcription Factor Info

Studied Phenotype

 .

Related DT Changes

 Up regulating

Detailed Description

 Mothers against decapentaplegic homolog 4 (SMAD4) has been reported to activate the transcription of CACNA2D3 gene in epithelial ovarian cancer condition, which leads to an increased expression of the drug transporter Voltage-dependent calcium channel alpha-2/delta-3.
References
1 Transcriptional network analysis identifies BACH1 as a master regulator of breast cancer bone metastasis. J Biol Chem. 2012;287(40):33533-44.
2 hTFtarget: A Comprehensive Database for Regulations of Human Transcription Factors and Their Targets. Genomics Proteomics Bioinformatics. 2020 Apr;18(2):120-344. (ID:ENSG00000157445)
3 Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells. Mol Cell Biol. 2008;28(8):2732-44.
4 Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma. Neuro Oncol. 2013;15(3):279-89.
5 Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer. Mol Endocrinol. 2014;28(12):2012-24.
6 Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor. Oncotarget. 2012;3(2):183-94.
7 Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS One. 2009;4(8):e6589.
8 Genome-wide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators. Dev Cell. 2011;20(5):597-609.
9 Regulatory crosstalk between lineage-survival oncogenes KLF5, GATA4 and GATA6 cooperatively promotes gastric cancer development. Gut. 2015;64(5):707-19.
10 The transcriptional regulator BCL6 participates in the secondary gene regulatory response to vitamin D. Biochim Biophys Acta. 2015;1849(3):300-8.
11 Global analysis of in vivo EGR1-binding sites in erythroleukemia cell using chromatin immunoprecipitation and massively parallel sequencing. Electrophoresis. 2010;31(17):2936-43.
12 Alternatively spliced isoforms of WT1 control podocyte-specific gene expression. Kidney Int. 2015;88(2):321-31.
13 Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha. BMC Genomics. 2014;15(1):520.
14 SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin. Nucleic Acids Res. 2015;43(2):848-61.
15 Molecular interactions between HNF4a, FOXA2 and GABP identified at regulatory DNA elements through ChIP-sequencing. Nucleic Acids Res. 2009;37(22):7498-508.
16 FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index. Breast Cancer Res Treat. 2015;154(1):23-32.
17 Genome-wide analysis of p63 binding sites identifies AP-2 factors as co-regulators of epidermal differentiation. Nucleic Acids Res. 2012;40(15):7190-206.
18 Genome-wide Runx2 occupancy in prostate cancer cells suggests a role in regulating secretion. Nucleic Acids Res. 2012;40(8):3538-47.
19 ChIP-seq defined genome-wide map of TGF/SMAD4 targets: implications with clinical outcome of ovarian cancer. PLoS One. 2011;6(7):e22606.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.